CoronaVac COVID-19 Vaccine Is Less Effective Against the P.1 Brazil Variant
- LABE
- 8 de jul. de 2021
- 1 min de leitura
A new study presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and published in The Lancet Microbe, shows that antibodies generated by CoronaVac, an inactivated COVID-19 vaccine, work less well against the P.1 Brazil (Gamma) variant.
Comentários